SUNOVION CNS DEVELOPMENT CANADA ULC - FORM 10-Q - EX-32.1 - EXHIBIT 32.1 - August 14, 2015

Attached files

file filename
EX-3.2 - EXHIBIT 3.2 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex3-2.htm
EX-4.7 - EXHIBIT 4.7 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-7.htm
EX-3.1 - EXHIBIT 3.1 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex3-1.htm
EX-4.4 - EXHIBIT 4.4 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-4.htm
EX-4.8 - EXHIBIT 4.8 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-8.htm
EX-4.5 - EXHIBIT 4.5 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-5.htm
EX-4.6 - EXHIBIT 4.6 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-6.htm
EX-4.3 - EXHIBIT 4.3 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-3.htm
EX-4.1 - EXHIBIT 4.1 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-1.htm
EX-4.2 - EXHIBIT 4.2 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex4-2.htm
EX-10.3 - EXHIBIT 10.3 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-3.htm
EX-31.1 - EXHIBIT 31.1 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex31-1.htm
EX-10.7 - EXHIBIT 10.7 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-7.htm
EX-10.2 - EXHIBIT 10.2 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-2.htm
EX-10.8 - EXHIBIT 10.8 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-8.htm
EX-10.1 - EXHIBIT 10.1 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-1.htm
EX-10.9 - EXHIBIT 10.9 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-9.htm
EX-10.6 - EXHIBIT 10.6 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex10-5.htm
EX-31.2 - EXHIBIT 31.2 - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_ex31-2.htm
10-Q - FORM 10-Q - SUNOVION CNS DEVELOPMENT CANADA ULCv416297_10q.htm

 

Exhibit 32.1

 

CERTIFICATIONS
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Cynapsus Therapeutics Inc. (the “Company”) for the period ended June 30, 2015 (the “Report”), the undersigned hereby certify in their capacities as Chief Executive Officer and Chief Financial Officer of the Company, respectively, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:

 

1.          the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.          the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: August 14, 2015 By:  /s/ Anthony Giovinazzo
    Anthony Giovinazzo
    President and Chief Executive Officer
    (principal executive officer)
     
Dated: August 14, 2015 By: /s/ Andrew Williams
    Andrew Williams
    Chief Operating Officer and Chief Financial Officer
    (principal financial officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

SUNOVION CNS DEVELOPMENT CANADA ULC Reports